653586-90-4

Upstream product

• 173422-40-7 (3R,4R)-1-(tert-butoxycarbonyl)-4-(furan-2-yl)-3-(triisopropylsilyloxy)azetidin-2-one 
• 564476-29-5 7-(triethylsilyl)-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-baccatin III 
• 810683-27-3 C₃₃H₄₂O₁₃ 
• 564476-26-2 C₄₉H₈₂O₁₂Si₃ 
• 564476-27-3 2-debenzoyl-2-(2,5-dimethoxybenzoyl)-10-deacetylbaccatin 
• 204580-30-3 10-O-deacetyl-2-O-debenzoyl-7,10,13-O-tris(triethylsilyl)baccatin III 
• 194720-19-9 7,10,13-tris(triethylsilyl)-10-deacetylbaccatin III 
• 32981-86-5 10-deacetylbaccatin III 

Downstream Products

• 889470-82-0 10-acetoxy-2'-(triisopropylsilyloxy)-3'-dephenyl-3'-(2-furyl)-2-debenzoyl-2-(2,5-dimethoxybenzoyl)-docetaxel 

Relevant academic research and scientific papers

Cytotoxic agents comprising new taxanes

The present invention relates to novel cytotoxic agents and their therapeutic use. More specifically, the invention relates to novel cytotoxic agents comprising taxanes and their therapeutic use. These novel cytotoxic agents have therapeutic use as a resu

Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors

The use of drug-antibody conjugates affords a method for the targeted delivery of anticancer drugs specifically to cancer cells. Monoclonal antibodies alone usually do not possess high therapeutic efficacy, however, they are capable of targeting tumor mar

Cytotoxic agents containing novel potent taxanes and their therapeutic use

Included within the scope of the present invention are potent taxanes containing a linking group. Also included is a cytotoxic agent comprising one or more taxanes linked to a cell binding agent. A therapeutic composition for inducing cell death in select